Compare Gilead Sciences, Inc. (GILD) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Valero Energy Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.52 (market cap $163.51B), while Valero Energy Corporation trades at $301.35 (market cap $86.90B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | VLO | |
|---|---|---|
Market Cap | $163.51B | $86.90B |
Sector | Health | Energy |
52-Week High | $155.80 | $301.43 |
52-Week Low | $108.22 | $131.77 |
Enterprise Value | $178.05B | $92.66B |
Dividend Yield | 2.49% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Valero Energy (VLO) trades at $302.33, up 0.3% on the day, with strong technical momentum and bullish moving average signals. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.22 surpassing expectations of $3.16. Revenue trends show a decline from $176.4B in 2022 to $122.7B in 2025, but net income margins remain positive. Analyst sentiment is predominantly bullish, with 20 buy ratings and a consensus price target of $276.22. Recent news highlights refining margin strength and Middle East supply tensions as key drivers.
VLO's outlook is supported by elevated refining margins and strategic positioning, though declining revenue and compressed profit margins pose risks. Investment opportunities include potential upside from continued earnings beats and favorable industry dynamics, while risks involve volatile energy markets and competitive pressures. The stock's current price near resistance at $306 suggests cautious optimism, with fundamental strength balancing macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
